The Valley Desk

NCT06192576 · Observational study

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

Overall registry status Recruiting

Conditions Acid Sphingomyelinase Deficiency, Niemann-Pick Diseases

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov